Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H1 2018
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H1 2018
SUMMARY
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) pipeline Target constitutes close to 32 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Leukocyte Surface Antigen CD47 - Pipeline Review, H1 2018, outlays comprehensive information on the Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - CD47 (Cluster of Differentiation 47) or integrin associated protein (IAP) is a transmembrane protein encoded by the CD47 gene. It has a role in both cell adhesions by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus (By similarity).
It acts as a receptor for SIRPA. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and co-stimulates T-cell activation. It plays an important role in membrane transport and/or integrin dependent signal transduction. It prevents premature elimination of red blood cells.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 14 and 10 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular and Metabolic Disorders which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Lymphoma, Diffuse Large B-Cell Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Relapsed Multiple Myeloma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Cutaneous T-Cell Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Bladder Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Diabetic Retinopathy, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Ischemia Reperfusion Injury, Kidney Transplant Rejection, Leiomyosarcoma, Leukemias, Marginal Zone B-cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Metastatic Breast Cancer, Metastatic Melanoma, Mycosis Fungoides, Myeloproliferative Disorders, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Peripheral T-Cell Lymphomas (PTCL), Sezary Syndrome, Small-Cell Lung Cancer and Squamous Cell Carcinoma.
Furthermore, this report also reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) pipeline Target constitutes close to 32 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Leukocyte Surface Antigen CD47 - Pipeline Review, H1 2018, outlays comprehensive information on the Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - CD47 (Cluster of Differentiation 47) or integrin associated protein (IAP) is a transmembrane protein encoded by the CD47 gene. It has a role in both cell adhesions by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus (By similarity).
It acts as a receptor for SIRPA. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and co-stimulates T-cell activation. It plays an important role in membrane transport and/or integrin dependent signal transduction. It prevents premature elimination of red blood cells.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 14 and 10 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular and Metabolic Disorders which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Lymphoma, Diffuse Large B-Cell Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Relapsed Multiple Myeloma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Cutaneous T-Cell Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Bladder Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Diabetic Retinopathy, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Ischemia Reperfusion Injury, Kidney Transplant Rejection, Leiomyosarcoma, Leukemias, Marginal Zone B-cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Metastatic Breast Cancer, Metastatic Melanoma, Mycosis Fungoides, Myeloproliferative Disorders, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Peripheral T-Cell Lymphomas (PTCL), Sezary Syndrome, Small-Cell Lung Cancer and Squamous Cell Carcinoma.
Furthermore, this report also reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)
- The report reviews Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics and enlists all their major and minor projects
- The report assesses Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Overview
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Companies Involved in Therapeutics Development
Aurigene Discovery Technologies Ltd
Celgene Corp
Forty Seven Inc
GigaGen Inc
Hummingbird Bioscience Pte Ltd
KAHR medical Ltd
NovImmune SA
PharmAbcine Inc
Sorrento Therapeutics Inc
Surface Oncology Inc
Synthon Holdings BV
Trillium Therapeutics Inc
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Drug Profiles
ABP-500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALX-148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUR-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUR-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-6H12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit CD47 and PDL1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-90002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FSI-189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Inhibit CD47 for glioblastoma and Non-Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMBD-004A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMBD-004B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hu-5F9G4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-2502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-2504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAHR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit CD47 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit CD47 for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit CD47 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD47 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-1701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-1801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit CD47 for Immuno-Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PSTx-23 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD47 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRF-231 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ti-061 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTI-621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTI-622 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Dormant Products
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Product Development Milestones
Featured News & Press Releases
Jun 03, 2018: Forty Seven Announces Proof-of-Concept Data from Two Clinical Trials of 5F9 In Patients with Advanced Solid Tumors and Non-Hodgkins Lymphoma
May 17, 2018: Alexo Therapeutics Initiates ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors and Lymphoma
May 17, 2018: Forty Seven to Present Preliminary Data from its Ongoing Phase 1 Clinical Trial of 5F9 in Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association
May 16, 2018: Forty Seven to Present Clinical Data on 5F9, its First-in-Class CD47 Antibody, at the 2018 American Society of Clinical Oncology Annual Meeting
Apr 18, 2018: Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 AACR Annual Meeting
Apr 12, 2018: Trillium Therapeutics To Report Preclinical Data On TTI-621 At The AACR Annual Meeting 2018
Apr 12, 2018: Trillium Therapeutics To Report Preclinical Data On TTI-622 At The AACR Annual Meeting 2018
Apr 10, 2018: Trillium Therapeutics Provides Update on Its TTI-621 Clinical Program
Apr 10, 2018: Trillium Therapeutics Provides Update on TTI-622 Program
Mar 20, 2018: Trillium Therapeutics TTI-621 Receives Orphan Drug Designation for the Treatment of Cutaneous T-Cell Lymphoma
Mar 20, 2018: Surface Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of SRF231
Jan 17, 2018: Trillium Therapeutics Enhances Senior Management Team to Support Further Clinical Development of TTI-621
Dec 11, 2017: Trillium Therapeutics Provides Update on Its TTI-621 Program at the American Society of Hematology 59th Annual Meeting
Dec 06, 2017: Forty Seven Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia
Nov 13, 2017: Trillium Therapeutics TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Overview
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Companies Involved in Therapeutics Development
Aurigene Discovery Technologies Ltd
Celgene Corp
Forty Seven Inc
GigaGen Inc
Hummingbird Bioscience Pte Ltd
KAHR medical Ltd
NovImmune SA
PharmAbcine Inc
Sorrento Therapeutics Inc
Surface Oncology Inc
Synthon Holdings BV
Trillium Therapeutics Inc
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Drug Profiles
ABP-500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALX-148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUR-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUR-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-6H12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit CD47 and PDL1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-90002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FSI-189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Inhibit CD47 for glioblastoma and Non-Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMBD-004A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMBD-004B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hu-5F9G4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-2502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-2504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAHR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit CD47 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit CD47 for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit CD47 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD47 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-1701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-1801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit CD47 for Immuno-Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PSTx-23 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD47 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRF-231 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ti-061 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTI-621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTI-622 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Dormant Products
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Product Development Milestones
Featured News & Press Releases
Jun 03, 2018: Forty Seven Announces Proof-of-Concept Data from Two Clinical Trials of 5F9 In Patients with Advanced Solid Tumors and Non-Hodgkins Lymphoma
May 17, 2018: Alexo Therapeutics Initiates ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors and Lymphoma
May 17, 2018: Forty Seven to Present Preliminary Data from its Ongoing Phase 1 Clinical Trial of 5F9 in Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association
May 16, 2018: Forty Seven to Present Clinical Data on 5F9, its First-in-Class CD47 Antibody, at the 2018 American Society of Clinical Oncology Annual Meeting
Apr 18, 2018: Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 AACR Annual Meeting
Apr 12, 2018: Trillium Therapeutics To Report Preclinical Data On TTI-621 At The AACR Annual Meeting 2018
Apr 12, 2018: Trillium Therapeutics To Report Preclinical Data On TTI-622 At The AACR Annual Meeting 2018
Apr 10, 2018: Trillium Therapeutics Provides Update on Its TTI-621 Clinical Program
Apr 10, 2018: Trillium Therapeutics Provides Update on TTI-622 Program
Mar 20, 2018: Trillium Therapeutics TTI-621 Receives Orphan Drug Designation for the Treatment of Cutaneous T-Cell Lymphoma
Mar 20, 2018: Surface Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of SRF231
Jan 17, 2018: Trillium Therapeutics Enhances Senior Management Team to Support Further Clinical Development of TTI-621
Dec 11, 2017: Trillium Therapeutics Provides Update on Its TTI-621 Program at the American Society of Hematology 59th Annual Meeting
Dec 06, 2017: Forty Seven Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia
Nov 13, 2017: Trillium Therapeutics TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
Pipeline by Celgene Corp, H1 2018
Pipeline by Forty Seven Inc, H1 2018
Pipeline by GigaGen Inc, H1 2018
Pipeline by Hummingbird Bioscience Pte Ltd, H1 2018
Pipeline by KAHR medical Ltd, H1 2018
Pipeline by NovImmune SA, H1 2018
Pipeline by PharmAbcine Inc, H1 2018
Pipeline by Sorrento Therapeutics Inc, H1 2018
Pipeline by Surface Oncology Inc, H1 2018
Pipeline by Synthon Holdings BV, H1 2018
Pipeline by Trillium Therapeutics Inc, H1 2018
Dormant Projects, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
Pipeline by Celgene Corp, H1 2018
Pipeline by Forty Seven Inc, H1 2018
Pipeline by GigaGen Inc, H1 2018
Pipeline by Hummingbird Bioscience Pte Ltd, H1 2018
Pipeline by KAHR medical Ltd, H1 2018
Pipeline by NovImmune SA, H1 2018
Pipeline by PharmAbcine Inc, H1 2018
Pipeline by Sorrento Therapeutics Inc, H1 2018
Pipeline by Surface Oncology Inc, H1 2018
Pipeline by Synthon Holdings BV, H1 2018
Pipeline by Trillium Therapeutics Inc, H1 2018
Dormant Projects, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Aurigene Discovery Technologies Ltd
Celgene Corp
Forty Seven Inc
GigaGen Inc
Hummingbird Bioscience Pte Ltd
KAHR medical Ltd
NovImmune SA
PharmAbcine Inc
Sorrento Therapeutics Inc
Surface Oncology Inc
Synthon Holdings BV
Trillium Therapeutics Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Aurigene Discovery Technologies Ltd
Celgene Corp
Forty Seven Inc
GigaGen Inc
Hummingbird Bioscience Pte Ltd
KAHR medical Ltd
NovImmune SA
PharmAbcine Inc
Sorrento Therapeutics Inc
Surface Oncology Inc
Synthon Holdings BV
Trillium Therapeutics Inc
